Skip to the main content.
Facebook Instagram Linkedin X YouTube Medium

megamenu-services

 

Turn Vision into Velocity with the Innovation CRO

Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.

All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.

Explore our Services

megamenu-solutions-expertise

 

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Solutions

Expertise

megamenu-company-2

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Explore our Company

Dasiglucagon Demonstrates Reduced Costs in the Treatment of Severe Hypoglycemia in a Budget Impact Model

admin.veranex : Mar 24, 2025 10:22:50 PM

Commercialization

Jordan Hinahara and Thomas Goss, members of our Commercial Strategy and Market Access team, contributed to the budget impact model. The objective was to evaluate the economic impact of dasiglucagon compared with available glucagon treatments for SHE management, considering direct cost of treatment and health care resource utilization.

Read the Model

Webinar: Precision Medicine and Alzheimer’s Disease: Overcoming Biomarker Testing Barriers for Alzheimer’s Disease Patients

Susannah Ashcroft : Mar 24, 2025 10:22:45 PM

Tuesday, October 03, 2023 | 12pm EDT / 11am CDT / 9am PDT / 5pm BST (UK) / 6pm CEST (EU-Central)

Read More

Study by Veranex and Thermo Fisher Highlights Payer Budget Impact of Novel Test for Kidney Transplant Rejection

admin.veranex : Mar 24, 2025 10:23:06 PM

By developing a U.S. payer budget impact model and associated manuscript for Thermo Fisher’s Molecular Microscope® MMDx®-Kidney (a microarray...

Commercialization
Read More
Recent Study Co-Authored by Veranex to be Presented at ISPOR 2024

Recent Study Co-Authored by Veranex to be Presented at ISPOR 2024

Veranex : Mar 24, 2025 10:23:06 PM

225,000 vitrectomy surgeries are performed annually in the U.S. A time-driven cost analysis conducted at a US academic hospital found the...

Commercialization
Read More